Shorter James
Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, United States of America.
Curr Opin Genet Dev. 2017 Jun;44:1-8. doi: 10.1016/j.gde.2017.01.008. Epub 2017 Feb 14.
Protein misfolding and aggregation unify several devastating neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. There are no effective therapeutics for these disorders and none that target the reversal of the aberrant protein misfolding and aggregation that cause disease. Here, I showcase important advances to define, engineer, and apply protein disaggregases to mitigate deleterious protein misfolding and counter neurodegeneration. I focus on two exogenous protein disaggregases, Hsp104 from yeast and gene 3 protein from bacteriophages, as well as endogenous human protein disaggregases, including: (a) Hsp110, Hsp70, Hsp40, and small heat-shock proteins; (b) HtrA1; and (c) NMNAT2 and Hsp90. I suggest that protein-disaggregase modalities can be channeled to treat numerous fatal and presently incurable neurodegenerative diseases.
蛋白质错误折叠和聚集是包括阿尔茨海默病、帕金森病和肌萎缩侧索硬化症在内的几种毁灭性神经退行性疾病的共同特征。目前尚无针对这些疾病的有效治疗方法,也没有针对导致疾病的异常蛋白质错误折叠和聚集进行逆转的治疗方法。在此,我展示了在定义、设计和应用蛋白质解聚酶以减轻有害蛋白质错误折叠和对抗神经退行性变方面取得的重要进展。我重点介绍两种外源性蛋白质解聚酶,即来自酵母的Hsp104和来自噬菌体的基因3蛋白,以及内源性人类蛋白质解聚酶,包括:(a) Hsp110、Hsp70、Hsp40和小分子热休克蛋白;(b) HtrA1;以及(c) NMNAT2和Hsp90。我认为蛋白质解聚酶疗法可用于治疗多种致命且目前无法治愈的神经退行性疾病。